Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
EGFR has emerged as a primary area of interest in cancer research, with biopharmaceuticals like Imclone's Erbitux and Amgen's Vectibix targeting the protein, but its multiple isoforms have made it difficult to predict these drugs' effectiveness, said Yale professor Nita Maihle.
Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."
Molecular Templates to Screen Targets for ImClone
The firms will use Molecular Templates' Direct Select Platform to create Engineered Toxin Bodies libraries that will be screened to identify potential drug candidates.
With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
Although Qiagen is prioritizing Rx/Dx partnerships with pharma, that doesn't mean it won't look into bringing tests to market with payors or on its own.
Sep 2, 2009
DxS to Team with BMS, ImClone on Erbitux Dx
Feb 4, 2009